hotspot -WSS

hotspot

author：leisure time 2025-09-29 01:35:40 - browse：8317

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Cassava Sciences’ Alzheimer’s clinical trials should be halted

WSS

Results on Novartis prostate cancer therapy could expand its use

US soldier in North Korean custody after crossing DMZ line

Study: Hearing aids may slow cognitive decline in those at risk

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

FDA clears Verve to begin U.S. study of gene

15 die by electrocution after transformer explodes in northern India

hotspot

hotspot

hotspot

Bright Health sells Medicare Advantage business to Molina

Merck, Daiichi strike cancer drug pact worth up to $22 billion

New air purifier tech could be key to improving indoor air quality

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Medical leaders decry Supreme Court decision on affirmative action

STAT Readout: Friday, Oct. 20 biotech updates

In age of alternative facts, a scholarly course on calling out crap

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

Bright Health sells Medicare Advantage business to Molina

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

explore

J&J lung cancer data amount to new salvo against AstraZeneca

Cassava Sciences’ Alzheimer’s clinical trials should be halted

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Twill hunts for pharma partner to market its depression app

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Questions loom on AstraZeneca cancer drug as safety concerns ebb

knowledge

entertainment

entertainment

hotspot